Skip to main content

Table 4 The single- and combined- synergizing, or resistance-inducing effects of Navitoclax on cellular apoptosis

From: BH3-mimetics: recent developments in cancer therapy

Cancer Cell Type Combined Apoptosis Ref
AML Primary cells dasatinib [141]
AML/ALL Jurkat, Molt-4 wogonin synergized [142]
Cervical SiHa, CaSki A-1210477 synergized [139]
CRC HCT116, DLD1, SW48, HT29, HCT-8 apigenin synergized [143]
CRC, Liver Huh7, HepG2, BEL7402, HCT116, DLD1, AGS sorafenib synergized [144]
CRC/Melanoma Colo-205 AZD6244 resistance [145]
Esophageal SKGT-4, KATO-TN, YES-6 fluorouracil synergized [146]
Esophageal EC109, HKESC-2, CaES-17 -single- [147]
HNSCC HN12 fenretinide synergized [148]
Liver Huh7 TRAIL resistance [149]
Lung H1650 and H1975 src-inhibitors synergized [150]
Non-small cell lung LC2, PC10 cisplatin synergized [151]
Small cell lung H209 vorinostat synergized [152]
Lymphoma DoHH-2 and SuDHL-4 rapamycin [153]
Neuroblastoma SH-SY5Y and CHLA-119 norcantharidin synergized [154]
Prostate LNCaP and PC3 paclitaxel synergized [155]
Prostate PC3, C4–2B, C4–2, DU145 MLN2238 synergized [156]
Ovarian Numerous paclitaxel/gemcitabine synergized [157]
Liver, Prostate, Cervical, CRC, NSCLC Hep3B, PC3, HCT-116, SW480, and SW620, H1299, SK-BR-3, HeLa metformin synergized [158]
  1. The cancer types are highlighted in bold (left column), the evaluation of single therapy alone is highlighted by -single-, non-synergy is highlighted by ‘-‘and the corresponding studies are referenced in the column on the right (Ref). Abbreviations: AML Acute Myelogenous Leukemia, ALL Acute Lymphoblastic Lymphoma, CRC Colorectal cancer, HNSCC Head and Neck Squamous Cell Carcinoma, NSCLC Non-small cell lung cancer